Fundraise / allotmentNotableFiled on BSE ·
Evonile Pharma Limited approves ₹90 crore rights issue to raise funds
Novartis India Ltd · Pharmaceuticals & Biotechnology
What the filing says
- Board approved raising up to ₹90 crore via partly paid-up equity shares on rights basis
- Rights Issue Committee formed to finalize terms including price, ratio, record date, and allotment
- Postal Ballot notice approved and new corporate website www.evonilepharma.com launched
Why it's rated notable: not yet binding (letter of intent, proposal or subject to approvals)
Original filing
Announcement under Regulation 30 (LODR)-Raising of Funds
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies Ltd
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Novartis India Ltd
- Fundraise / allotmentNotableEvonile Pharma Ltd approves rights issue to raise up to ₹900 crore
- Acquisition / mergerNotableNovartis India Limited acquires Minipress trademarks from Pfizer for ₹1250 crore
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentRane Holdings LtdRane Holdings approves ₹80.85 crore investment in ZF Lifetec Rane JV rights issue
- Fundraise / allotmentCapital Infra TrustCapital Infra Trust submits post-Institutional Placement unit holding pattern
- Fundraise / allotmentCapital Infra TrustCapital Infra Trust raises ₹1,115 crore via QIP for acquiring six HAM road assets
- Fundraise / allotmentPaisalo Digital LtdPaisalo Digital Limited approves Q2 and H1 FY2026-27 unaudited financial results
- Fundraise / allotmentBluestone JewelBlueStone Jewellery to raise up to ₹300 crore via non-convertible debentures
- Fundraise / allotmentAvalon Technologies LtdAvalon Technologies Limited announces Board meeting on Oct 27, 2026 for fund raising
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.